Line 34: |
Line 34: |
| |} | | |} |
| ==Definition / Description of Disease== | | ==Definition / Description of Disease== |
− | An indolent primary cutaneous CD4+ T-cell lymphoproliferative disorder for which conservative treatment such as excision and local radiation is known to be effective. They express at least one follicular T-helper (TFH) marker, except for CD10, and thus is suspected to arise from TFH cells. | + | An indolent primary cutaneous peripheral CD4+ T-cell lymphoproliferative disorder for which conservative treatment such as excision and local radiation therapy is known to be effective. |
| + | |
| + | They express at least one follicular T-helper (TFH) marker, except for CD10. |
| + | |
| + | The differential diagnosis includes<ref name=":1" /><ref name=":4">Jaffe, E. et al. (2017). Hematopathology (2nd ed.). Elsevier.</ref> |
| + | |
| + | * other cutaneous T-cell lymphomas (CTCLs) |
| + | * marginal zone lymphoma |
| + | * reactive benign cutaneous lymphoid proliferation |
| | | |
| | | |
| Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span> | | Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span> |
| ==Synonyms / Terminology== | | ==Synonyms / Terminology== |
− | Primary cutaneous CD4+ small/medium T-cell lymphoma (not preferred due to indolent clinical course)<ref name=":0">Swerdlow, S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues (4th Ed), pp.401</ref> | + | Primary cutaneous CD4+ small/medium T-cell lymphoma (not preferred due to indolent clinical course)<ref name=":0">Swerdlow, S.H. et al. (2017). WHO classification of tumours of haematopoietic and lymphoid tissues (4th Ed). IARC</ref> |
| ==Epidemiology / Prevalence== | | ==Epidemiology / Prevalence== |
| Previously considered an uncommon disease but may be underestimated. | | Previously considered an uncommon disease but may be underestimated. |
| | | |
− | Comprising up to 6% of cutaneous T-cell lymphomas (CTCLs). <ref>{{Cite journal|last=Willemze|first=Rein|last2=Cerroni|first2=Lorenzo|last3=Kempf|first3=Werner|last4=Berti|first4=Emilio|last5=Facchetti|first5=Fabio|last6=Swerdlow|first6=Steven H.|last7=Jaffe|first7=Elaine S.|date=2019-04-18|title=The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/30635287/|journal=Blood|volume=133|issue=16|pages=1703–1714|doi=10.1182/blood-2018-11-881268|issn=1528-0020|pmc=6473500|pmid=30635287}}</ref> | + | Comprising up to 6% of CTCLs. <ref>{{Cite journal|last=Willemze|first=Rein|last2=Cerroni|first2=Lorenzo|last3=Kempf|first3=Werner|last4=Berti|first4=Emilio|last5=Facchetti|first5=Fabio|last6=Swerdlow|first6=Steven H.|last7=Jaffe|first7=Elaine S.|date=2019-04-18|title=The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/30635287/|journal=Blood|volume=133|issue=16|pages=1703–1714|doi=10.1182/blood-2018-11-881268|issn=1528-0020|pmc=6473500|pmid=30635287}}</ref> |
| | | |
| One study reported local prevalence of 12.5% of all CTCLs, making it the second most common cutaneous lymphoma following mycosis fungoides.<ref name=":1" /> | | One study reported local prevalence of 12.5% of all CTCLs, making it the second most common cutaneous lymphoma following mycosis fungoides.<ref name=":1" /> |
Line 53: |
Line 61: |
| Slow growing | | Slow growing |
| | | |
− | Solitary skin nodule/papule/plaque<ref name=":1" /><ref name=":0" /> | + | Solitary skin nodule/papule/plaque, reddish/purple<ref name=":4" /><ref name=":1" /><ref name=":0" /> |
| | | |
| Multiple lesions in a small number of patients<ref name=":1" /><ref name=":0" /> | | Multiple lesions in a small number of patients<ref name=":1" /><ref name=":0" /> |
Line 65: |
Line 73: |
| | | |
| *Dense dermal lymphoid infiltrate, often with nodular or diffuse pattern<ref name=":2">{{Cite journal|last=Beltraminelli|first=Helmut|last2=Leinweber|first2=Bernd|last3=Kerl|first3=Helmut|last4=Cerroni|first4=Lorenzo|date=2009-06|title=Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases|url=https://pubmed.ncbi.nlm.nih.gov/19461234|journal=The American Journal of Dermatopathology|volume=31|issue=4|pages=317–322|doi=10.1097/DAD.0b013e31819f19bb|issn=1533-0311|pmid=19461234}}</ref><ref name=":3">{{Cite journal|last=Cetinözman|first=Fatma|last2=Jansen|first2=Patty M.|last3=Willemze|first3=Rein|date=2012-01|title=Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21989349|journal=The American Journal of Surgical Pathology|volume=36|issue=1|pages=109–116|doi=10.1097/PAS.0b013e318230df87|issn=1532-0979|pmid=21989349}}</ref> | | *Dense dermal lymphoid infiltrate, often with nodular or diffuse pattern<ref name=":2">{{Cite journal|last=Beltraminelli|first=Helmut|last2=Leinweber|first2=Bernd|last3=Kerl|first3=Helmut|last4=Cerroni|first4=Lorenzo|date=2009-06|title=Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases|url=https://pubmed.ncbi.nlm.nih.gov/19461234|journal=The American Journal of Dermatopathology|volume=31|issue=4|pages=317–322|doi=10.1097/DAD.0b013e31819f19bb|issn=1533-0311|pmid=19461234}}</ref><ref name=":3">{{Cite journal|last=Cetinözman|first=Fatma|last2=Jansen|first2=Patty M.|last3=Willemze|first3=Rein|date=2012-01|title=Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21989349|journal=The American Journal of Surgical Pathology|volume=36|issue=1|pages=109–116|doi=10.1097/PAS.0b013e318230df87|issn=1532-0979|pmid=21989349}}</ref> |
− | *Tends to extend to subcutaneous tissue<ref name=":3" /><ref name=":2" /> | + | *Tends to extend to superficial subcutaneous tissue<ref name=":3" /><ref name=":2" /> |
| *Lack significant epidermotropism and folliculotropism<ref name=":3" /> | | *Lack significant epidermotropism and folliculotropism<ref name=":3" /> |
| *Predominantly small/medium-size T-cells with mild-moderate cytological atypia<ref name=":3" /><ref name=":2" /><ref name=":1" /><ref name=":0" /> | | *Predominantly small/medium-size T-cells with mild-moderate cytological atypia<ref name=":3" /><ref name=":2" /><ref name=":1" /><ref name=":0" /> |
Line 160: |
Line 168: |
| |}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | | |}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. |
| ==Epigenomic Alterations== | | ==Epigenomic Alterations== |
− | N/ | + | N/A |
| ==Genes and Main Pathways Involved== | | ==Genes and Main Pathways Involved== |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span> | | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span> |
Line 167: |
Line 175: |
| !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations | + | |Not found |
− | |<span class="blue-text">EXAMPLE:</span> MAPK signaling
| + | |N/A |
− | |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
| + | |N/A |
− | |-
| |
− | |<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
| |
− | |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation
| |
− | |<span class="blue-text">EXAMPLE:</span> Unregulated cell division
| |
− | |-
| |
− | |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations
| |
− | |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling | |
− | |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program | |
| |} | | |} |
| ==Genetic Diagnostic Testing Methods== | | ==Genetic Diagnostic Testing Methods== |
− | PCR for clonal T-cell receptor gene rearrangement (clonal rearrangement present in majority of cases). <ref name=":1" /> | + | PCR for clonal T-cell receptor gene rearrangement (clonal rearrangement present in majority of cases). <ref name=":1" /><ref name=":3" /> |
| ==Familial Forms== | | ==Familial Forms== |
| <span style="color:#0070C0">N/A </span> | | <span style="color:#0070C0">N/A </span> |